These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23386922)

  • 41. Finding the Path to Biobank Sustainability Through Sound Business Planning.
    Henderson M; Simeon-Dubach D; Albert M
    Biopreserv Biobank; 2015 Dec; 13(6):385-6. PubMed ID: 26697906
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost model for biobanks.
    Gonzalez-Sanchez MB; Lopez-Valeiras E; Morente MM; Fernández Lago O
    Biopreserv Biobank; 2013 Oct; 11(5):272-7. PubMed ID: 24835258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Analysis and Comparison of Medication Therapy Management Cost-Avoidance vs. Fee-for-Service Financial Models.
    Schuh MJ
    Consult Pharm; 2015 May; 30(5):291-7. PubMed ID: 25979129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research.
    Meredith AJ; Slotty A; Matzke L; Babinszky S; Watson PH
    Biopreserv Biobank; 2015 Oct; 13(5):356-62. PubMed ID: 26418967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Introduction to Starting a Biobank.
    Harati MD; Williams RR; Movassaghi M; Hojat A; Lucey GM; Yong WH
    Methods Mol Biol; 2019; 1897():7-16. PubMed ID: 30539430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The State of Cloud-Based Biospecimen and Biobank Data Management Tools.
    Paul S; Gade A; Mallipeddi S
    Biopreserv Biobank; 2017 Apr; 15(2):169-172. PubMed ID: 28300421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example.
    Schwenkglenks M; Preiswerk G; Lehner R; Weber F; Szucs TD
    J Epidemiol Community Health; 2006 Jan; 60(1):24-30. PubMed ID: 16361451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advancing Professionalization of Biobank Business Operations: A Worldwide Survey.
    Henderson MK; Goldring K; Simeon-Dubach D
    Biopreserv Biobank; 2019; 17(1):71-75. PubMed ID: 30412417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ensuring Effective Utilization of Biospecimens: Design, Marketing, and Other Important Approaches.
    Bledsoe MJ; Sexton KC
    Biopreserv Biobank; 2019 Jun; 17(3):248-257. PubMed ID: 31188625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Commentary on Improving Biospecimen Utilization by Classic Biobanks: Identifying Past and Minimizing Future Mistakes.
    Grizzle WE; Sexton KC
    Biopreserv Biobank; 2019 Jun; 17(3):243-247. PubMed ID: 30508389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Australian Biobank Certification Scheme: A Study of Economic Costs to Participating Biobanks.
    Ling R; Rush A; Carter C; Carpenter J; Watson PH; Byrne JA; Searles A
    Biopreserv Biobank; 2018 Feb; 16(1):53-58. PubMed ID: 29215912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward a Synergistic Operating Model for Westmead Research Hub Biobanks: A Questionnaire Study.
    St George G; Wang XM; Linton J; Douglas N; Carpenter JE; Clarke CL; Heads JA
    Biopreserv Biobank; 2019 Dec; 17(6):570-576. PubMed ID: 31429584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Current modalities and concepts on access and use of biospecimen samples and associated data for research from human biobanks].
    Siddiqui R; Semler SC
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Mar; 59(3):317-24. PubMed ID: 26809822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bridging the financial gap through providing contract services: a model for publicly funded clinical biobanks.
    Kozlakidis Z; Mant C; Cason J
    Biopreserv Biobank; 2012 Aug; 10(4):357-60. PubMed ID: 24849884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacoeconomic analysis of the collection and preservation of samples in the biobank of the "Instituto Nacional de Cancerología" in Mexico City.
    Ruíz-Godoy LM; Baez-Revueltas FB; de Lourdes Suarez-Roa M; Maldonado-Martínez H; Enriquez-Carcamo V; Colín-González AL; Meneses-García A
    Cell Tissue Bank; 2018 Dec; 19(4):569-580. PubMed ID: 30155658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biospecimen Complexity and the Evolution of Biobanks.
    Hartman V; Matzke L; Watson PH
    Biopreserv Biobank; 2019 Jun; 17(3):264-270. PubMed ID: 31188632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dental care for the elderly through a Capped-fee funding model: Optimising outcomes for primary government dental services.
    Conquest JH; Skinner J; Kruger E; Tennant M
    Gerodontology; 2017 Dec; 34(4):486-492. PubMed ID: 28836354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The landscape of biobanks in Poland-characteristics of Polish biobanking units at the beginning of BBMRI.pl organization.
    Chróścicka A; Paluch A; Kozera Ł; Lewandowska-Szumieł M
    J Transl Med; 2021 Jun; 19(1):267. PubMed ID: 34158056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biobank Continuity Management: A Survey of Biobank Professionals.
    Church TD; Richmond FJ
    Biopreserv Biobank; 2019 Oct; 17(5):410-417. PubMed ID: 31017454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancing Cooperation Between Academic Biobanks and Biomedical Industry: Better Mutual Understanding and New Collaborative Models Are Needed.
    Simeon-Dubach D; Roehrl MH; Hofman P; Puchois P
    Biopreserv Biobank; 2020 Apr; 18(2):144-149. PubMed ID: 32043910
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.